Johnson & Johnson: Legal Woes Are Detrimental But Not Fatal [Seeking Alpha]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Seeking Alpha
JNJ's potentially massive talc-related legal liabilities will likely affect buying sentiment. However, it's easy to forget that JNJ is a fundamentally strong business with robust free cash flow profitability. Investors should be careful about buying JNJ when overvalued, but it's not. Dip-buyers were assessed to have returned with conviction last week, providing JNJ investors another solid buying opportunity. Johnson & Johnson ( NYSE: JNJ ) investors have had to deal with massive downside volatility as JNJ continues underperforming its healthcare sector ( XLV ) peers. I maintained my bullish thesis on JNJ in my previous article. However, JNJ's continued underperformance has Recommended For You Recommended For You About JNJ Stock
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Phase 2 data for ERLEADA® ?(apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised prostate cancer shows 100 percent biochemical free recurrence rate more than two years post-surgery [Yahoo! FinYahoo! Fin
- Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery [Yahoo! Finance]Yahoo! Finance
- TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer [Yahoo! Finance]Yahoo! Finance
- TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer [Yahoo! Finance]Yahoo! Finance
- BIZCLIK MEDIA LAUNCHES MAY EDITION OF SUPPLY CHAIN DIGITAL AND PROCUREMENT MAGAZINE [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 4/16/24 - Beat
JNJ
Sec Filings
- 5/3/24 - Form 4
- 5/1/24 - Form 10-Q
- 5/1/24 - Form 8-K
- JNJ's page on the SEC website